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In Africa, incidence and prevalence of drug-resistant 
tuberculosis have been assumed to be low. However, 
investigation after a 2005 outbreak of extensively drug-
resistant tuberculosis in KwaZulu-Natal Province, South 
Africa, found that the incidence rate for multidrug-resistant 
tuberculosis in KwaZulu-Natal was among the highest 
globally and would be higher if case-ﬁ   nding efforts were 
intensiﬁ  ed.
I
n Africa, resistance to anti-tuberculosis (TB) drugs 
has been assumed to be low (1). In 2002, the national 
drug resistance survey showed rates of multidrug-resistant 
(MDR) TB in South Africa to be 3.0% among all TB 
cases, 1.6% among new cases, and 6.6% among previously 
treated cases (2). Surveys in other African countries have 
yielded MDR TB rates of <3% among all TB cases, low 
compared with >20% reported from former Soviet Union 
countries; however, MDR TB rates may not be as low as 
previously estimated (3–7). In response to a 2005 outbreak 
of extensively drug-resistant (XDR) TB in KwaZulu-Natal 
Province, South Africa (8), we conducted a retrospective 
study of the extent and distribution of drug-resistant TB in 
the province. 
The Study 
KwaZulu-Natal Province, population ≈10 million, 
contains 11 health districts with 68 hospitals in the public 
health sector. We analyzed existing laboratory records from 
the only 2 laboratories in the province that conducted culture 
and drug-sensitivity testing as part of routine clinical care. 
Since 2001, all samples from patients with MDR TB in the 
province were tested for susceptibility to second-line anti-
TB drugs, except in 2004 and 2005, when 82% (1,143) and 
55% (1,277) of samples, respectively, were not tested for 
ﬂ  uoroquinolones. From 2006 on, all culture-positive cases 
in the province were tested for susceptibility to ﬁ  rst-line and 
second-line anti-TB drugs. We reviewed laboratory results 
from 2001 through 2007 and determined the number of 
MDR TB and XDR TB cases for each district. To provide 
context for the 2005 XDR TB outbreak at the Church of 
Scotland Hospital (COSH) in KwaZulu-Natal Province (8), 
we also analyzed geographic distribution and time trends. 
Per deﬁ  nition, the number of MDR TB cases includes all 
XDR TB cases.
According to national guidelines, samples for culture 
should be collected from persons who are being initially 
examined for retreatment, those for whom treatment has 
failed, those whose sputum smear results are negative 
but who have clinical signs of TB and do not respond to 
antibacterial drug treatment (excluding TB treatment), and 
those suspected of having HIV and TB co-infection. Despite 
the guidelines, the intensity with which cultures were 
requested varied among districts. We compared culture-
taking practices with prevalence of MDR TB per district 
during the same time frame. Culture-taking practices were 
derived from the number of patients for whom a culture 
was requested during 12 months after March 2006 and 
were analyzed per district and per 100,000 population. The 
proportion of identiﬁ  ed MDR TB patients who received 
treatment with second-line anti-TB drugs was calculated by 
dividing the number of patients with laboratory-conﬁ  rmed 
MDR TB by the number of patients admitted to King 
George V Hospital, the only TB hospital in the province 
that treated patients with MDR TB during the same period. 
(Detailed methods available from K.W. upon request.)
In 2007, a total of 2,799 cases (28 cases/100,000 
population) of MDR TB were identiﬁ  ed in KwaZulu-Natal. 
TB prevalence was 1,200 cases/100,000 population, and 
MDR accounted for 2.3% of reported cases in the province 
(http://arxiv.org/abs/1107.1800). XDR TB cases accounted 
for 9.6% of MDR TB cases (Table).
In 2007, MDR TB in the districts ranged from 10 
(uThukela) to 57 (Umkhanyakude) cases per 100,000 
population (Table). Incidence of MDR TB was highest 
for Umkhanyakude and Umzinyathi districts (location 
of COSH) (8). The proportion of MDR TB cases that 
were XDR TB cases also varied among districts (1.2%–
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(Umkhanyakude and Umzinyathi) had the highest and the 
lowest XDR TB prevalence, respectively (Table).
From 2001 to 2007, the level of MDR TB increased 
>10-fold, from 216 cases to 2,799 cases, respectively 
(Figure 1, panel A), and XDR TB increased from 6 cases 
to 270 cases, respectively (Figure 1, panel B). In part, the 
increase reﬂ  ects increased sampling, which tripled between 
2002 and 2007, from ≈40,000 to >120,000 samples tested 
each year. The variation in MDR TB prevalence between 
districts could be attributed to differences in culture-taking 
practice (Spearman correlation coefﬁ  cient 0.82; p = 0.001) 
(Figure 2). XDR TB prevalence, expressed as proportion 
of MDR TB, was not affected by culture-taking practices 
because all positive cultures were tested for ﬁ  rst-line and 
second-line anti-TB drugs.
XDR TB has been in KwaZulu-Natal Province since 
2001 and was ﬁ  rst  identiﬁ   ed in eThekwini. XDR TB 
increased rapidly in 2005 when the outbreak was identiﬁ  ed, 
and 72% of all XDR TB cases in the province were at COSH 
(Figure 1, panel B). As a result of this outbreak, culture-
taking practices in the rest of the province increased, and 
in 2007, the proportion of identiﬁ  ed XDR TB cases in 
the province that were at COSH had decreased to 37%. 
Excluding Umzinyathi, an average of 6.5% of all MDR TB 
cases were also XDR TB.
Within 12 months after March 2006, only 32% (896) 
of 2,784 patients with laboratory-identiﬁ  ed MDR TB had 
received treatment with second-line drugs. During 2005–
2006, the average time between sputum collection and 
admission to King George V Hospital was 16 weeks. The 
delay reﬂ  ects turnaround time for culture and sensitivity 
testing (4–6 weeks), delay in returning results to the 
referring health facility (not all sites have Internet access), 
tracing of patients, and hospital admission waiting time.
Conclusions 
In 2007, South Africa ranked fourth among countries 
with the highest estimated number of MDR TB cases (9). 
Within South Africa, KwaZulu-Natal Province had the 
highest prevalence of drug-resistant TB and accounted for 
38% (2,799) of 7,350 MDR TB cases and 50% (270) of 536 
XDR TB cases in the country (10,11).
The reported MDR TB incidence rate per 100,000 
population of KwaZulu-Natal is among the highest 
worldwide. Districts Umkhanyakude and Umzinyathi 
reported 57 and 48 cases/100,000 population, respectively, 
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Table. Cases of MDR and XDR TB, KwaZulu-Natal Province, South Africa, 2007* 
District  
All TB 
cases
MDR TB 
cases 
XDR TB 
cases 
MDR/all TB 
cases, % 
XDR/MDR cases, % 
(95% CI) 
No. MDR cases/ 
100,000 population 
eThekwini 45,019  1,014  64 2.3 6.3 (4.9–8.0)  31.7
Ugu 10,618  226 9 2.1 4.0 (1.8–7.4)  31.0
uMgungundlovu 10,687  247 36 2.3 14.6 (10.4–19.6)  25.7
uThukela 6,129 69 8 1.1 11.6 (5.1–21.6)  10.1
Umzinyathi 5,522 226 120 4.1 53.1 (46.4–59.7)  47.8
Amajuba 3,578 61 2 1.7 3.3 (0.4–11.3)  12.6
Zululand 8,478 171 6 2.0 3.5 (1.3–7.5)  20.5
Umkhanyakude 6,991  337 4 4.8 1.2 (0.3–3.0)  56.8
Uthungulu 11,876  233 11 2.0 4.7 (2.4–8.3)  25.4
iLembe 5,007 118 6 2.4 5.1 (1.9–10.7)  20.3
Sisonke 5,313  61 4 1.1 6.6 (1.8–15.9)  12.9
Total 119,218 2,799  270 2.3 9.6  (8.6–10.8)  28.2
*MDR, multidrug-resistant; XDR, extensively drug-resistant; TB, tuberculosis; CI, confidence interval. 
Figure 1. Prevalence of drug-resistant tuberculosis (TB) in the 11 
districts of KwaZulu-Natal, South Africa, 2001–2007. A) Multidrug-
resistant (MDR) TB; B) extensively drug-resistant (XDR) TB. White 
bar sections, Church of Scotland Hospital; black bar sections, the 
rest of KwaZulu-Natal Province.Drug-Resistant TB, KwaZulu-Natal, South Africa
more than the highest previously reported estimate of 35 
cases/100,000 population in Karakalpakstan, Uzbekistan 
(12). Because many patients never have a sample taken 
for culture and sensitivity testing, the identiﬁ  ed level of 
MDR TB is an underestimate. 
After the 2005 outbreak, COSH increased vigilance 
for drug resistance, and culture and sensitivity testing was 
conducted for all patients with suspected TB. If other clinics 
and hospitals in the province requested as many cultures 
as COSH, MDR TB in KwaZulu-Natal would amount 
to 68 cases/100,000 population, with an estimated 6,750 
MDR TB cases and 526 XDR TB cases per year, 2–3× 
more than currently identiﬁ  ed (Figure 2). Furthermore, the 
increase in XDR TB during 2006–2007 suggests ongoing 
transmission of XDR TB.
Study limitations include unavailability of data to 
assess trends in culture-taking practices, so we could not 
evaluate how culture-taking practices may have inﬂ  uenced 
the increase in reporting of MDR TB over time. Also 
unavailable were data for categorizing MDR TB cases as 
new or retreatment. 
Our ﬁ  ndings show that incidence rates of MDR TB in 
KwaZulu-Natal could be higher than previously estimated. 
Since 2007, steps have been taken to validate and implement 
rapid diagnostic tests for all TB patients in the province 
and to increase access to MDR TB treatment by increasing 
bed capacity and decentralizing the MDR TB treatment 
program. The challenge is ensuring that all patients with 
a new diagnosis of MDR TB have access to treatment. 
Similarly, ongoing transmission of TB must be reduced by 
implementation of sound infection control measures.
Acknowledgments
We thank Adrian Koopman for advice on the spelling of 
Zulu district names.
The situational analysis of drug resistance in KwaZulu-
Natal was prepared in response to a request from the Provincial 
Department of Health, KwaZulu Natal, with ﬁ  nancial  and 
technical support of the World Health Organization, and would 
not have been possible without the collaboration and involvement 
of National Health Laboratory Services, Inkosi Albert Luthuli 
Central Hospital TB Laboratory, King George V Hospital, COSH, 
and the Department of Health. The World Health Organization 
supported study design; collection, analysis, and interpretation of 
data; and writing of the report. The decision to submit the article 
for publication was made by the World Health Organization and 
the South Africa Department of Health.
Dr Wallengren is the clinical core manager at KwaZulu-
Natal Research Institute for TB and HIV at University of 
KwaZulu-Natal. Her research interests include TB, HIV, TB/HIV 
co-infection, epidemiology, and basic science.
References
    1.   World Health Organization. Anti-tuberculosis resistance in the 
world. Report no. 4. Geneva: The Organization; 2008.
  2.   Weyer K, Van der Walt M, Brand J, Lancaster J, Levin J. Survey 
of tuberculosis drug resistance in South Africa: ﬁ  nal report. Preto-
ria (South Africa): Medical Research Council; 2004. p. 1–19 [cited 
2011 May 7]. http://www.mrc.ac.za/operationaltb/reports.htm
  3.   Institute of Medicine. Addressing the threat of drug-resistant tuber-
culosis. A realistic assessment of the challenge. In: Workshop sum-
mary, 2008 Nov 5; Washington.  Washington: National Academies 
Press; 2009 [cited 2011 May 7].  http://www.ncbi.nlm.nih.gov/
books/NBK45006/pdf/TOC.pdf
  4.   Ben Amor Y, Nemser B, Singh A, Sankin A, Schluger N. Under-
reported threat of multidrug-resistant tuberculosis in Africa. Emerg 
Infect Dis. 2008;14:1345–52. doi:10.3201/eid1409.061524
  5.   Cohen T, Colijn C, Wright A, Zignol M, Pym A, Murray M. Chal-
lenges in estimating the total burden of drug-resistant tuberculosis. 
Am J Respir Crit Care Med. 2008;177:1302–6 [Epub 2008 Mar 27]. 
doi:10.1164/rccm.200801-175PP
  6.   Nunes EA, De Capitani EM, Coelho E, Joaquim OA, Figueiredo 
IR, Cossa AM, et al. Patterns of anti-tuberculosis drug resistance 
among HIV-infected patients in Maputo, Mozambique, 2002–2003. 
Int J Tuberc Lung Dis. 2005;9:494–500.
    7.    Chirenda J, Menzies H, Moalosi G, Anisimova V, Radisowa K, 
Bachhuber M, et al. The trend of resistance to anti-tuberculosis drugs 
in Botswana: results from the 4th national anti-tuberculosis drug re-
sistance survey. In: Abstracts of the 40th Union World Conference 
on Lung Health; Cancun, Mexico; Dec 3–7, 2009. Int J Tuberc Lung 
Dis. 2009 (Suppl 1);13:S3 [cited 2011 May 7]. http://www.tbpolicy.
ru/news/index.php?id=309&ﬁ  le=350
  8.   Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo 
U, et al. Extensively drug-resistant tuberculosis as a cause of death 
in patients co-infected with tuberculosis and HIV in a rural area 
of South Africa. Lancet. 2006;368:1575–80. doi:10.1016/S0140-
6736(06)69573-1
  9.   World Health Organization. Global tuberculosis control: epidemiol-
ogy, strategy, ﬁ  nancing: report 2009. Publication no. WHO/HTM/
TB/2009.411. Geneva: The Organization; 2009.
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 10, October 2011  1915
Figure 2. Culture-taking practice correlation with identiﬁ  ed 
multidrug-resistant tuberculosis (MDR TB) prevalence in the 11 
districts of KwaZulu-Natal Province and in the Church of Scotland 
Hospital (COSH), South Africa, 2001–2007. Because of the high 
level of culture-taking at COSH, COSH data were subtracted 
from the Umzinyathi district data. Black line indicates the level of 
MDR TB that would be identiﬁ  ed if the whole province requested 
the same number of culture and sensitivity testing as COSH.10.   Department of Health, Republic of South Africa. Statistical notes. Ex-
tremely drug resistant tuberculosis (XDR-TB) in South Africa. May 
2008 [cited 2011 May 7]. http://www.doh.gov.za/facts/stats-notes/
2008/xdr-tb.pdf
11.   Department of Health, Republic of South Africa. Tuberculosis stra-
tegic plan for South Africa, 2007–2011 [cited 2011 May 7].  http://
www.doh.gov.za/docs/summit/tb.pdf
12.   Zager EM, McNerney R. Multidrug-resistant tuberculosis. BMC In-
fect Dis. 2008;8:10. doi:10.1186/1471-2334-8-10
Address for correspondence: Kristina Wallengren, KwaZulu-Natal 
Research Institute for Tuberculosis and HIV, Private Bag X7, Congella 
4013, South Africa; email: kristina.wallengren@k-rith.org
DISPATCHES
1916  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 10, October 2011